Importantly, overexpression of CXCR7 predicted poor clinical outcome in a cohort of breast cancer patients, suggesting that blocking CXCR7 signaling may be a potential therapeutic approach to inhibit highly metastatic and invasive breast cancer, which is a major cause of mortality in breast cancer patients. This evidence concerns the gene ACKR3 and breast cancer.